InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000

July 19, 2016

InMed Announces Appointment of Eric A. Adams as CEO, President and Director

June 16, 2016

InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors

June 13, 2016

InMed Updates Progress of its Epidermolysis Bullosa Program

May 18, 2016

InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures

May 4, 2016

InMed Announces Update on Biosynthesis Project

February 16, 2016

InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler

November 23, 2015

InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa

November 4, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000

November 2, 2015

InMed Appoints Paul Brennan as President & Chief Executive Officer

September 3, 2015

InMed Commences Development of Proprietary Drug Delivery System

September 2, 2015

InMed Appoints Paul Brennan to the Board of Directors

August 25, 2015

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program

August 20, 2015

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)

August 6, 2015

InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline

June 3, 2015

InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)

May 26, 2015

InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases

May 12, 2015

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750

May 7, 2015

InMed Engages Peter Mountford as Strategic Advisor

May 5, 2015

InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.

April 30, 2015

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
BayMedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

CORPORATE

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.